NCT06268470View on ClinicalTrials.gov

Antiplatelet Therapy in Chronic Urticaria

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 1, 2018

Primary Completion Date

March 1, 2024

Study Completion Date

May 1, 2024

Conditions
Chronic Urticaria
Interventions
DRUG

Desloratadine plus cilostazol and dipyridamole

Desloratadine 20 mg/day plus cilostazol 150 mg/day and dipyridamole 50 mg/day

DRUG

Desloratadine

Desloratadine 20 mg/day

Trial Locations (1)

10330

Faculty of Medicine, Chulalongkorn University, Bangkok

All Listed Sponsors
lead

Chulalongkorn University

OTHER

NCT06268470 - Antiplatelet Therapy in Chronic Urticaria | Biotech Hunter | Biotech Hunter